Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Zenas BioPharma, Inc. (ZBIO : NSDQ)

• Company Description    Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass. Number of Employees: 167

• Price / Volume Information    Yesterday's Closing Price: $18.97 Daily Weekly Monthly 20 Day Moving Average: 555,534 shares Shares Outstanding: 63.13 (millions) Market Capitalization: $1,197.63 (millions) Beta: -0.61 52 Week High: $44.60 52 Week Low: $8.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.60% -2.42% 12 Week -28.03% -33.47% Year To Date -47.76% -49.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 852 Winter Street Suite 250 - Waltham,MA 02451 USA ph: 857-271-2954 fax: - zenas@argotpartners.com http://www.zenasbio.com

• General Corporate Information    Officers Leon O. Moulder - Chief Executive Officer and Director Jennifer Fox - ChiefFinancial Officer;Chief Business Officer Patricia Allen - Director James Boylan - Director Patrick Enright - Director Peer Information Zenas BioPharma, Inc. (CORR.) Zenas BioPharma, Inc. (RSPI) Zenas BioPharma, Inc. (CGXP) Zenas BioPharma, Inc. (BGEN) Zenas BioPharma, Inc. (GTBP) Zenas BioPharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98937L105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 63.13 Most Recent Split Date: (:1) Beta: -0.61 Market Capitalization: $1,197.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.57 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -82.50% vs. Previous Quarter: -4.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 100.00% ROE 03/31/26 - -99.99 12/31/25 - -85.64 09/30/25 - -71.61 ROA 03/31/26 - -58.06 12/31/25 - -61.86 09/30/25 - -56.08 Current Ratio 03/31/26 - 11.94 12/31/25 - 5.61 09/30/25 - 5.66 Quick Ratio 03/31/26 - 11.94 12/31/25 - 5.61 09/30/25 - 5.66 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - -3,778.16 09/30/25 - -1,264.37 Book Value 03/31/26 - 5.32 12/31/25 - 4.51 09/30/25 - 4.66 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 1.04 12/31/25 - 0.32 09/30/25 - 0.37 Debt-to-Capital 03/31/26 - 51.08 12/31/25 - 24.51 09/30/25 - 27.09

Powered by Zacks Investment Research ©